Physician profile
Vanitha Bala
NPI 1386662351
$7,191.53
in general payments reported to CMS, 2019-2025
24 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $198 · 2021: $1,044 · 2022: $1,640 · 2023: $1,016 · 2024: $1,757 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.23 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,402.00 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $920.40 | 2022-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $772.64 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $513.39 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.78 | 2021-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $377.10 | 2021-2024 | Wegovy |
| Gilead Sciences, INC. | $313.51 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.28 | 2021-2024 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $291.09 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $284.17 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $239.34 | 2024-2025 | Interstim, Signia |
| Celgene Corporation | $236.67 | 2022-2024 | Zeposia |
| Apollo Endosurgery US INC | $145.63 | 2023 | Overstitch Endoscopic Suturing System |
| Dexcom, INC. | $142.44 | 2024 | Dexcom G7 Gss (161) |
| E.R. Squibb & Sons, L.L.C. | $125.25 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.40 | 2025 | Omvoh |
| Boston Scientific Corporation | $123.24 | 2020 | |
| Redhill Biopharma INC. | $98.40 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Nestle Healthcare Nutrition INC. | $91.65 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $86.60 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.27 | 2020 | |
| Ironwood Pharmaceuticals, INC | $37.95 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $19.20 | 2023 | Sutab |
| Romark Laboratories, Lc | $4.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanitha Bala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.